Suppliers and packagers for generic pharmaceutical drug: TRIPTORELIN PAMOATE

TRIPTORELIN PAMOATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Azurity	TRIPTODUR KIT	triptorelin pamoate	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	208956	NDA	Azurity Pharmaceuticals, Inc.	24338-150-20	1 KIT in 1 CARTON (24338-150-20) * 2 mL in 1 VIAL * 2 mL in 1 SYRINGE, GLASS	2017-09-08
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	020715	NDA	Verity Pharmaceuticals Inc.	74676-5902-1	1 KIT in 1 CARTON (74676-5902-1) * 2 mL in 1 VIAL, SINGLE-DOSE (74676-5902-0) * 2 mL in 1 SYRINGE	2000-06-15
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	021288	NDA	Verity Pharmaceuticals Inc.	74676-5904-1	1 KIT in 1 CARTON (74676-5904-1) * 2 mL in 1 VIAL, SINGLE-DOSE (74676-5904-0) * 2 mL in 1 SYRINGE	2001-06-29

Triptorelin Pamoate: A Supply Chain Analysis

Last updated: February 19, 2026

This report details the global supply landscape for triptorelin pamoate, a synthetic analog of gonadotropin-releasing hormone (GnRH) used in the treatment of prostate cancer, endometriosis, and precocious puberty. It identifies key raw material suppliers, active pharmaceutical ingredient (API) manufacturers, and finished dosage form producers, assessing their capacities, regulatory compliance, and market positioning.

What is Triptorelin Pamoate?

Triptorelin pamoate is a long-acting injectable formulation of triptorelin. Triptorelin is a decapeptide that initially stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, leading to a surge in testosterone in men and estrogen in women. However, continuous administration results in downregulation of GnRH receptors, suppressing LH and FSH production and consequently reducing sex hormone levels. This mechanism is exploited to manage hormone-dependent conditions. The pamoate salt formulation allows for a sustained release of the active peptide over several weeks or months, reducing the frequency of administration [1].

Triptorelin pamoate is indicated for:

• Advanced prostate cancer: To reduce testosterone levels.
• Endometriosis: To suppress ovarian function and reduce estrogen levels.
• Central precocious puberty: To halt premature pubertal development in children.

The drug is typically administered via intramuscular or subcutaneous injection, with formulations available for one-month, three-month, and six-month release profiles [2].

Key Raw Material Suppliers

The synthesis of triptorelin, the peptide active ingredient, requires specific amino acids and reagents. The quality and reliable supply of these precursors are critical for API manufacturers.

Amino Acid Precursors

Triptorelin is a decapeptide with the sequence pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2. The key amino acid building blocks include:

• L-Glutamic acid (pGlu): Cyclized form of glutamic acid.
• L-Histidine
• L-Tryptophan
• L-Serine
• L-Tyrosine
• D-Tryptophan: A non-proteinogenic amino acid isomer.
• L-Leucine
• L-Arginine
• L-Proline
• Glycine

Suppliers of these amino acids often operate in the broader fine chemical and pharmaceutical intermediate markets. Major global suppliers include:

• Ajinomoto Co., Inc. (Japan): A leading producer of amino acids for pharmaceutical and food industries.
• Evonik Industries AG (Germany): Offers a comprehensive portfolio of amino acids, including pharmaceutical-grade products.
• Amino GmbH (Germany): Specializes in the production and distribution of amino acids and their derivatives.
• CJ CheilJedang Corporation (South Korea): A significant global producer of fermentation-derived amino acids.
• Kyowa Hakko Bio Co., Ltd. (Japan): A subsidiary of Kirin Holdings, known for its fermentation-based amino acid production.

Specialty Reagents and Protecting Groups

Peptide synthesis involves complex chemical reactions requiring specific coupling reagents, deprotection agents, and solid-phase resins. Key reagents include:

• Coupling agents: Such as HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) or HOBt (hydroxybenzotriazole) derivatives.
• Protecting groups: Fmoc (9-fluorenylmethyloxycarbonyl) or Boc (tert-butyloxycarbonyl) for amino group protection.
• Solvents: High-purity solvents like N,N-Dimethylformamide (DMF) or N-Methyl-2-pyrrolidone (NMP).
• Solid supports: For solid-phase peptide synthesis (SPPS), such as Wang resins or Rink amide resins.

Suppliers for these specialized chemicals include:

• Merck KGaA (Germany): Through its MilliporeSigma brand, offers a wide range of peptide synthesis reagents and consumables.
• Iris Biotech GmbH (Germany): Focuses on amino acid derivatives and reagents for peptide synthesis.
• Bachem Holding AG (Switzerland): While primarily an API manufacturer, Bachem also supplies custom peptide building blocks and reagents.
• Aktin Biotech (China): Offers a range of peptide synthesis reagents and raw materials.

Pamoic Acid

Pamoic acid is essential for forming the pamoate salt. It is a dicarboxylic acid derived from naphthalene.

• Suppliers: Pamoic acid is a relatively less common specialty chemical. Manufacturers typically include custom synthesis providers and fine chemical companies. Sourcing may involve specialized chemical suppliers in China and India, as well as Western European chemical synthesis firms. Direct identification of specific large-scale suppliers is challenging as it is often produced on demand or in smaller batch sizes compared to peptide precursors.

Active Pharmaceutical Ingredient (API) Manufacturers

The synthesis of triptorelin peptide is a complex process, typically involving solid-phase peptide synthesis (SPPS) or liquid-phase peptide synthesis (LPPS), followed by purification and salt formation.

Key API Manufacturers of Triptorelin Acetate (precursor to pamoate salt):

Company Name	Country	Primary Focus	Regulatory Approvals (Examples)	Notes
Bachem Holding AG	Switzerland	Peptide APIs, custom synthesis	FDA, EMA	One of the largest peptide manufacturers globally. Extensive experience with GnRH analogs.
PolyPeptide Group	Denmark	Custom peptide manufacturing	FDA, EMA	Significant capacity for complex peptides, including GnRH analogs. Operates multiple sites globally.
Peptonic Medical AB	Sweden	Peptide API development and manufacturing	N/A (focus on early-stage)	Developing proprietary peptide-based drug delivery systems. May offer custom synthesis services.
Novartis AG	Switzerland	Integrated pharmaceutical company	FDA, EMA	May produce triptorelin API internally for its branded products (e.g., Decapeptyl/Goserelix).
Ipsen S.A.	France	Pharmaceutical company	FDA, EMA	Originator of triptorelin formulations. Likely has in-house API manufacturing capabilities or long-term contracts.
Lee's Pharmaceutical	China	API and finished dosage form manufacturing	NMPA, potential international	A growing player in generic APIs and drug products.
China Biologic Products	China	Biologics and plasma-derived products	NMPA	May have peptide synthesis capabilities.
Various Indian API Firms	India	Generic API manufacturing	FDA, EMA (site-specific)	Numerous Indian companies (e.g., Lupin, Dr. Reddy's, Sun Pharma) have peptide synthesis capabilities, though triptorelin may be niche.

Process of API Synthesis and Salt Formation:

1. Peptide Synthesis: Automated SPPS is common for triptorelin. Amino acids are sequentially added to a growing peptide chain anchored to a solid resin. This method allows for efficient synthesis and purification. LPPS is also an option but is generally more complex for longer peptides.
2. Deprotection and Cleavage: Protecting groups are removed, and the completed peptide is cleaved from the resin.
3. Purification: High-performance liquid chromatography (HPLC) is used to purify the crude peptide, ensuring high purity (typically >98%).
4. Salt Formation: Purified triptorelin acetate (or another salt) is reacted with pamoic acid under controlled conditions to form triptorelin pamoate. This step requires careful control of stoichiometry and precipitation to achieve the desired crystal form and particle size for controlled release.
5. Drying and Milling: The triptorelin pamoate is dried and may be milled to achieve specific particle size distribution essential for depot formulation.

Capacity and Lead Times:

Large peptide API manufacturers like Bachem and PolyPeptide have significant annual capacities, capable of producing metric tons of peptide APIs. However, triptorelin may be a niche product within their broader portfolio. Custom synthesis projects can have lead times ranging from 6 to 18 months, depending on complexity, scale, and existing production schedules. For established generic products, there may be dedicated production lines, reducing lead times to a few months.

Finished Dosage Form (FDF) Manufacturers

The formulation of triptorelin pamoate into a long-acting injectable depot is a specialized process. It involves suspending the API in a suitable vehicle to ensure controlled release over extended periods. This typically requires microsphere or nanoparticle technology.

Key FDF Manufacturers and Contract Manufacturing Organizations (CMOs):

Company Name	Country	Primary Focus	Regulatory Approvals (Examples)	Notes
Ipsen S.A.	France	Branded triptorelin formulations (e.g., Decapeptyl)	FDA, EMA	Originator company. High-quality manufacturing for its proprietary products.
Teva Pharmaceutical	Israel	Generic pharmaceuticals, specialty generics	FDA, EMA	Known for developing generic versions of complex injectables. May have capabilities for triptorelin pamoate depots.
Dr. Reddy's Laboratories	India	Generic pharmaceuticals, complex injectables	FDA, EMA	Has invested in complex injectable manufacturing, including depot formulations.
Sun Pharmaceutical	India	Generic pharmaceuticals, specialty products	FDA, EMA	Possesses strong capabilities in sterile injectables and controlled-release technologies.
Boehringer Ingelheim	Germany	Pharmaceuticals, contract manufacturing	FDA, EMA	As a large CMO with expertise in injectables and sterile manufacturing, they could produce triptorelin pamoate depots.
Lonza Group AG	Switzerland	Biologics and chemical manufacturing, CDMO	FDA, EMA	A leading global CDMO with extensive experience in sterile injectables and complex drug delivery systems.
Catalent, Inc.	USA	CDMO for pharmaceuticals, biologics, and consumer health	FDA, EMA	Offers a wide range of drug delivery technologies, including sterile injectables and controlled-release formulations.
Almac Group	UK/USA	Pharmaceutical development and manufacturing services	FDA, EMA	Specializes in sterile injectable manufacturing, including complex depot formulations and lyophilization.
WuXi AppTec	China	CDMO services	FDA, EMA, NMPA	Offers comprehensive services from API to FDF manufacturing, including sterile injectables and controlled-release technologies.
Emergent BioSolutions	USA	Biologics manufacturing, CDMO	FDA	While focused on biologics, has expertise in sterile fill-finish and lyophilization that could be leveraged.

Formulation Technology:

Triptorelin pamoate depots are typically formulated using biodegradable polymers, most commonly Poly(lactic-co-glycolic acid) (PLGA). The API and PLGA are mixed, often with excipients, and then processed using techniques such as:

• Solvent evaporation: Where a solution of PLGA and API is emulsified and the solvent is evaporated, forming microspheres.
• Extrusion/Spheronization: For certain paste-like depots.

The choice of PLGA molecular weight, lactic:glycolic acid ratio, and manufacturing process parameters dictates the release kinetics, achieving one, three, or six-month duration.

Quality and Regulatory Considerations:

Manufacturing triptorelin pamoate FDF requires stringent adherence to Good Manufacturing Practices (GMP). Facilities must be capable of aseptic processing, lyophilization (if applicable), and sterile filtration. Analytical testing for drug release, particle size distribution, and stability is critical. Regulatory approvals are often specific to each market (e.g., FDA for the US, EMA for Europe, NMPA for China).

Market Dynamics and Key Players

The triptorelin pamoate market is characterized by a mix of originator and generic products.

• Originators: Ipsen's Decapeptyl/Trelstar and Pfizer's Goserelin (a similar GnRH analog, often considered in the same therapeutic class) represent established branded products. Novartis also has a presence with its GnRH analog formulations.
• Generics: The patent expiries of key triptorelin pamoate products have opened the door for generic manufacturers. Teva, Dr. Reddy's, Sun Pharma, and numerous other Indian and Chinese companies are active in developing and marketing generic triptorelin pamoate. The competition in the generic space drives price reductions.
• Geographic Focus: The primary markets are North America, Europe, and increasingly, Asia. Emerging markets are also adopting these treatments as healthcare access improves.

Challenges in the Supply Chain:

• Peptide Synthesis Complexity: Triptorelin is a decapeptide, and its synthesis requires specialized expertise and infrastructure. Impurities can arise from incomplete reactions, epimerization, or deletion sequences, necessitating rigorous purification.
• Controlled Release Formulation: Developing stable, long-acting injectable depots with predictable release profiles is technically challenging and requires advanced drug delivery expertise. Bioavailability can be variable if formulation is not optimized.
• Regulatory Hurdles: Obtaining regulatory approval for sterile injectables, especially long-acting depots, is a lengthy and costly process. Comparability studies and bioequivalence data are essential for generics.
• Raw Material Sourcing: Ensuring a consistent supply of high-purity amino acids and specialty reagents, particularly D-tryptophan, can be a bottleneck. Geopolitical factors or disruptions in global supply chains can impact availability and cost.
• Cost of Goods: Peptide synthesis and complex formulation technologies contribute to a higher cost of goods compared to small molecule drugs, impacting profitability, especially for generic players.

Future Trends:

• Advancements in Peptide Synthesis: Continuous improvement in SPPS technologies, including microwave-assisted synthesis and novel coupling reagents, could enhance efficiency and reduce costs.
• Novel Drug Delivery Systems: Research into alternative depot formulations, such as in-situ forming implants or nanoparticle-based systems, could offer improved patient compliance or therapeutic outcomes.
• Geographic Expansion: Growth in emerging markets is expected to drive demand for both branded and generic triptorelin pamoate.
• Biologics and Biosimilars: While triptorelin is a chemically synthesized peptide, the broader trend towards biologics might influence R&D focus. However, the established nature of peptide synthesis means triptorelin is unlikely to be directly impacted by biosimilar regulations.

Key Takeaways

• The triptorelin pamoate supply chain involves specialized amino acid suppliers, complex peptide API manufacturers, and advanced FDF formulators.
• Key API manufacturers include Bachem and PolyPeptide, with significant capacity and regulatory experience.
• Finished dosage form manufacturing is dominated by established pharmaceutical companies (originators and generics) and specialized CDMOs with expertise in sterile injectables and controlled-release technologies.
• Challenges include the technical complexity of peptide synthesis and depot formulation, stringent regulatory requirements, and raw material sourcing.
• The market is competitive, with a strong presence of generic products alongside established branded therapies.

Frequently Asked Questions

1. What are the primary challenges in sourcing D-Tryptophan for triptorelin synthesis? D-Tryptophan is a non-proteinogenic amino acid, meaning it is not commonly found in natural proteins. Its synthesis requires chiral separation or asymmetric synthesis, making it more costly and potentially subject to supply limitations compared to L-amino acids. Sourcing reliable, high-purity D-Tryptophan from specialized chemical manufacturers is critical.

2. How does triptorelin pamoate achieve its extended release profile? Triptorelin pamoate is formulated into a depot injection, typically using biodegradable polymeric microspheres, most commonly PLGA. The triptorelin pamoate is encapsulated within these microspheres. As the PLGA polymer slowly degrades in the body through hydrolysis, it releases the triptorelin peptide over a period of one, three, or six months, depending on the formulation's specific characteristics.

3. What is the significance of Good Manufacturing Practices (GMP) in triptorelin pamoate production? GMP compliance is paramount for all pharmaceutical manufacturing, particularly for injectable products. For triptorelin pamoate, GMP ensures the sterility of the final product, prevents contamination, guarantees the correct dosage and purity of the API, and validates the controlled-release characteristics of the depot formulation. Deviations can lead to product recalls, regulatory sanctions, and patient harm.

4. What are the key differences between triptorelin acetate and triptorelin pamoate? Triptorelin acetate is typically the salt form of the synthesized triptorelin peptide used as an intermediate. It is often a short-acting formulation or a precursor to other salt forms. Triptorelin pamoate is specifically designed as a long-acting depot formulation. The pamoate salt is less soluble and is used to create the sustained-release matrix when formulated into microspheres or other depot technologies, allowing for infrequent administration.

5. How is bioequivalence established for generic triptorelin pamoate products? For generic triptorelin pamoate, bioequivalence studies are required to demonstrate that the generic product delivers the same amount of triptorelin into the bloodstream over time as the reference listed drug. This typically involves pharmacokinetic studies in healthy volunteers or relevant patient populations, measuring drug concentrations in plasma at various time points after injection. The formulation technology and particle size distribution of the generic depot are critical for achieving bioequivalence.

Citations

[1] National Institutes of Health. (n.d.). Triptorelin. https://medlineplus.gov/druginfo/meds/a682221.html [2] Ipsen. (2023). Trelstar (triptorelin pamoate) Prescribing Information. Retrieved from manufacturer website or FDA database. [3] Bachem. (n.d.). Peptide Building Blocks and Reagents. Retrieved from Bachem official website. [4] PolyPeptide Group. (n.d.). Capabilities. Retrieved from PolyPeptide Group official website. [5] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from FDA's Drug@FDA database. [6] European Medicines Agency. (n.d.). EudraGMDP Database. Retrieved from EMA website. [7] Global API Manufacturers. (n.d.). Industry reports and company profiles. [8] Contract Development and Manufacturing Organization (CDMO) Websites and Industry Directories. (n.d.).